The position of combined medical treatment in acromegaly

Arch Endocrinol Metab. 2019 Nov-Dec;63(6):646-652. doi: 10.20945/2359-3997000000195.

Abstract

Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6):646-52.

Publication types

  • Review

MeSH terms

  • Acromegaly / drug therapy
  • Dopamine Agonists / administration & dosage*
  • Drug Therapy, Combination
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / analogs & derivatives*
  • Humans
  • Quality of Life
  • Receptors, Somatostatin / administration & dosage*
  • Receptors, Somatotropin / antagonists & inhibitors*
  • Somatostatin / administration & dosage
  • Somatostatin / analogs & derivatives*

Substances

  • Dopamine Agonists
  • Receptors, Somatostatin
  • Receptors, Somatotropin
  • Human Growth Hormone
  • Somatostatin
  • pasireotide
  • pegvisomant